Bill Commons

CA AB 2442

in committee

Peptides.

California · 2025-2026 Regular Session · lower

Follow this bill’s action updates (Atom)

Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.

Quick answers

Did CA AB 2442 pass?

Not yet. CA AB 2442 is in committee and has not come to a final vote. Latest recorded action (2026-05-14): In committee: Held under submission.

What is CA AB 2442 about?

Existing law establishes the State Department of Public Health, which, among other things, administers various programs that prevent disease and promote health. This bill would create the California Investigational Peptide and Novel Compound Research and Therapeutic Access Program and would require the department to convene a working group with specified members to study and make recommendations regarding the creation of a state-authorized research and investigational therapeutic framework, as specified. The bill would require the working group to study potential uses of investigational therapeutic compounds and novel peptide compounds, among other things, and to submit a report to the Legislature detailing its findings and recommendations no later than January 1, 2029. The bill would repeal these provisions on January 1, 2030.

Who sponsors CA AB 2442?

Patterson is the primary sponsor of CA AB 2442.

Description

Existing law establishes the State Department of Public Health, which, among other things, administers various programs that prevent disease and promote health. This bill would create the California Investigational Peptide and Novel Compound Research and Therapeutic Access Program and would require the department to convene a working group with specified members to study and make recommendations regarding the creation of a state-authorized research and investigational therapeutic framework, as specified. The bill would require the working group to study potential uses of investigational therapeutic compounds and novel peptide compounds, among other things, and to submit a report to the Legislature detailing its findings and recommendations no later than January 1, 2029. The bill would repeal these provisions on January 1, 2030.

Introduced
2026-03-19
Latest action
2026-05-14 — In committee: Held under submission.
Bill type
bill
Last updated
—

Subjects

Sponsors

  • Pattersonauthor

Committees

Not provided by source.

Action timeline

Newest first

  1. 2026-05-14

    In committee: Held under submission.

  2. 2026-05-06

    In committee: Set, first hearing. Referred to APPR. suspense file.

    referral-committee

  3. 2026-04-22

    From committee: Do pass and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 12. Noes 0.) (April 21). Re-referred to Com. on APPR.

    committee-passage,committee-passage-favorable,referral-committee

  4. 2026-04-16

    Re-referred to Com. on JUD.

    referral-committee

  5. 2026-04-15

    From committee: Do pass and re-refer to Com. on JUD. with recommendation: To Consent Calendar. (Ayes 16. Noes 0.) (April 14). Re-referred to Com. on JUD.

    committee-passage,committee-passage-favorable,referral-committee

  6. 2026-04-15

    From committee chair, with author's amendments: Amend, and re-refer to Com. on JUD. Read second time and amended.

    amendment-introduction,amendment-passage,committee-passage,reading-1,reading-2,referral-committee

  7. 2026-03-23

    Re-referred to Com. on HEALTH.

    referral-committee

  8. 2026-03-19

    From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.

    amendment-introduction,amendment-passage,committee-passage,reading-1,reading-2,referral-committee

  9. 2026-03-19

    Referred to Coms. on HEALTH and JUD.

    referral-committee

  10. 2026-02-21

    From printer. May be heard in committee March 23.

  11. 2026-02-20

    Read first time. To print.

    reading-1

Versions

  • 02/20/26 - Introduced — 2026-02-20Compare
  • 03/19/26 - Amended Assembly — 2026-03-19Compare
  • 04/15/26 - Amended Assembly — 2026-04-15Compare
  • AB2442Compare
  • (document, no version)Compare

Documents

Votes

  • Do pass and be re-referred to the Committee on [Judiciary] with recommendation: To Consent Calendar

    2026-04-14 · pass · 16-0

    Member-level votes (16)
    • Aguiar-Curry: yes
    • Addis: yes
    • Rogers: yes
    • Caloza: yes
    • Bonta: yes
    • Schiavo: yes
    • Carrillo: yes
    • Mark González: yes
    • Sharp-Collins: yes
    • Johnson: yes
    • Stefani: yes
    • Patel: yes
    • Patterson: yes
    • Chen: yes
    • Sanchez: yes
    • Ahrens: yes

  • Do pass and be re-referred to the Committee on [Appropriations] with recommendation: To Consent Calendar

    2026-04-21 · pass · 12-0

    Member-level votes (12)
    • Zbur: yes
    • Papan: yes
    • Connolly: yes
    • Bauer-Kahan: yes
    • Dixon: yes
    • Bryan: yes
    • Sanchez: yes
    • Kalra: yes
    • Harabedian: yes
    • Pacheco: yes
    • Macedo: yes
    • Stefani: yes

Related bills

No related bills recorded for this bill.

Official source

http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202520260AB2442

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T01:34:27.960412Z

Inspect retained evidence for changes recorded after evidence tracking began:

Source and document changesStatus and relationship changes

Session-wide evidence can include changes to other bills:

Bulk imports for this sessionSession dates and activity

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=CA&identifier=AB 2442. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.
  • Some documents have no extracted text yet, so version comparison may be limited.

See the methodology page for data sources and limitations.